Small Molecules
2 February 2013
GlaxoSmithKline starts Phase III study to test combined BRAF/MEK inhibition in patients with BRAF positive melanoma following surgery2 February 2013
Hyperion Therapeutics’ RAVICTI(TM) (glycerol phenylbutyrate) Liquid Receives FDA Approval for Treatment of Urea Cycle Disorders31 January 2013
Cerulean Announces First Patient Dosed in Randomized Phase 2 Study of CRLX101 in Advanced Small Cell Lung Cancer31 January 2013
Daiichi Sankyo and ArQule Enroll First Hepatocellular Carcinoma Patient into Global Phase 3 Trial for Tivantinib31 January 2013
Vanda Announces Phase IIb/III Clinical Study In Major Depressive Disorder Did Not Meet The Primary Endpoint31 January 2013
OncoEthix Doses First Patient in its Phase I Trial of OTX015, a BET Bromodomain Inhibitor for the Treatment of Hematologic Malignancies30 January 2013
ADVENTRX Initiates Pivotal Phase 3 Study of ANX-18830 January 2013
Endocyte to Advance Development of EC1069, a PSMA-Targeted Small Molecule Drug Conjugate Therapy for Prostate Cancer30 January 2013
Karolinska Development AB (Publ): Dilaforette – Phase II Study with Sevuparin for the Treatment of Severe Malaria Initiated30 January 2013
FDA Advisory Committee Recommends Approval for Boehringer Ingelheim’s Olodaterol for Maintenance Treatment of COPD29 January 2013
Anacor Pharmaceuticals Announces Positive Results From the First of Two Phase 3 Trials of Tavaborole for Onychomycosis29 January 2013
La Jolla Pharmaceutical Company Announces First Patient Treated in Clinical Trial of GCS-100 in Chronic Kidney Disease29 January 2013
Bausch + Lomb Initiates Phase 3 Program for Glaucoma Drug Candidate Licensed From Nicox28 January 2013
Nimbus Discovery Presents Preclinical Data on Sought-After ACC Inhibitors for the Treatment of Metabolic Syndrome and Diabetes27 January 2013
Belinostat has favorable safety profile in PTCL BELIEF study24 January 2013
CHANTIX (varenicline) Demonstrates Efficacy in Smokers Who Previously Attempted to Quit Smoking with CHANTIX24 January 2013
Curis Announces Dosing of First Patient in Phase I Clinical Trial of Dual PI3 Kinase and HDAC Inhibitor CUDC-907News Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports